No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BLFS BioLife Solutions
- 19.960
- -0.290-1.43%
Close Jun 18 16:00 ET
- 20.220
- +0.260+1.30%
Post 17:59 ET
919.53MMarket Cap-14056P/E (TTM)
20.634High19.630Low420.13KVolume20.220Open20.250Pre Close8.41MTurnover1.17%Turnover RatioLossP/E (Static)46.07MShares23.85052wk High2.76P/B718.23MFloat Cap8.92052wk Low--Dividend TTM35.98MShs Float72.188Historical High--Div YieldTTM4.96%Amplitude0.140Historical Low20.010Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Insider Sale: Todd Berard Sells 10,000 Shares of BioLife Solutions Inc (BLFS)
BioLife Solutions(BLFS.US) Officer Sells US$201.8K in Common Stock
$BioLife Solutions(BLFS.US)$ Officer Berard Todd sold 10,000 shares of common stock on Jun 14, 2024 at an average price of $20.18 for a total value of $201.8K.Source: Announcement What is statement of
Northland Securities Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $26
Northland Securities analyst Carl Byrnes maintains $BioLife Solutions(BLFS.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of 0
BioLife Solutions (NASDAQ:BLFS) Dips 5.5% This Week as Increasing Losses Might Not Be Inspiring Confidence Among Its Investors
While not a mind-blowing move, it is good to see that the BioLife Solutions, Inc. (NASDAQ:BLFS) share price has gained 19% in the last three months. But that cannot eclipse the less-than-impressive
BioLife Solutions (BLFS) Receives a Buy From Craig-Hallum
BioLife Solutions Introduces the CellSeal CryoCase at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and clo
Comments
BioLife Solutions, despite more cash than debt, is seen as risky due to lack of profitability and negative cash flow. The company's future financial health hinges on its earnings.
Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt? 1
The stock's low price indicates a potential buying opportunity. However, its high beta suggests volatility. The company's optimistic future outlook isn't fully reflected in the current share price.
BioLife Solutions' worrying forecast of increased losses and reduced revenues could wane investor confidence. The company's long-term business trajectory is vital for creating shareholder value.
Lack of insider transactions might be discouraging for the company's share outlook and the stated insider ownership is not really impressive.
Core points:
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg